Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5- mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1197-1212

  Atwell, Graham J ^a   Yang, Shangjin ^a   Pruijn, Frederik B ^a   Pullen, Susan M ^a   Hogg, Alison ^a   Patterson, Adam V ^a   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BENZAMIDE DERIVATIVE; MESYLIC ACID DERIVATIVE; MUSTARD GAS DERIVATIVE; NITROREDUCTASE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; HYDROGEN BOND; MALE; MOUSE; NONHUMAN; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BYSTANDER EFFECT; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ESCHERICHIA COLI PROTEINS; FEMALE; GENE THERAPY; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MICE; MICE, NUDE; MULTIVARIATE ANALYSIS; NITROGEN MUSTARD COMPOUNDS; NITROREDUCTASES; PRODRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 33947669761     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061062o     Document Type: Article

References (29)

1. Denny, W. A.; Wilson, W. R. Consideration for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 1986, 29, 879-887.
2. Siim, B. G.; Denny, W. A.; Wilson, W. R. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res. 1997, 9, 357-369.
3. Michael, N. P.; Brehm, J. K.; Anlezark, G. M.; Minton, N. P. Physical characterization of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. Microbiol. Lett. 1994, 124, 195-202.
4. Grove, J. I.; Searle, P. F.; Weedon, S. J.; Green, N. K.; McNeish, I. A.; Kerr, D. J. Virus-directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Des. 1999, 14, 461-472.
5. Green, N. K.; Kerr, D. J.; Mautner, V.; Harris, P. A.; Searle, P. F. The nitroreductase/CB1954 enzyme-prodrug system. Methods Mol. Med. 2004, 90, 459-477.
6. Knox, R. J.; Friedlos, F.; Marchbank, T.; Roberts, J. J. Bioactivation of CB 1954: Reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 1991, 42, 1691-1697.
7. Helsby, N. A.; Ferry, D. M.; Patterson, A. V.; Pullen, S. M.; Wilson, W. R. 2-amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer 2004, 90, 1084-1093.
8. Bridgewater, J. A.; Knox, R. J.; Pitts, J. D.; Collins, M. K.; Springer, C. J. The bystander effect of the nitroreductase/CB1954 enzyme/ prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 1997, 8, 709-717.
9. Djeha, A. H.; Hulme, A.; Dexter, M. T.; Mountain, A.; Young, L. S.; Searle, P. F.; Kerr, D. J.; Wrighton, C. J. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 2000, 7, 721-731.
10. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Helsby, N. A.; Hicks, K. O.; Denny, W. A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002, 62, 1425-1432.
11. Chung-Faye, G.; Palmer, D.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P. I.; Searle, P.; Seymour, L.; Harris, P. A.; Ferry, D.; Kerr, D. J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7, 2662-2668.
12. Bridgewater, J. A.; Springer, C. J.; Knox, R. J.; Minton, N. P.; Michael, N. P.; Collins, M. K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 1995, 31A, 2362-2370.
13. Tang, M. H.; Helsby, N. A.; Wilson, W. R.; Tingle, M. D. Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. Toxicology 2005, 216, 129-139.
14. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Coles, B.; Friedlos, F.; Knox, R. J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-1. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44, 2289-2295.
15. Helsby, N. A.; Atwell, G. J.; Yang, S.; Palmer, B. D.; Anderson, R. F.; Pullen, S. M.; Ferry, D. M.; Hogg, A.; Wilson, W. R.; Denny, W. A. Aziridinyldinitrobenzamides: Synthesis and structure-activity relationships for activation by E. coli nitroreductase. J. Med. Chem. 2004, 47, 3295-3307.
16. Palmer, B. D.; Wilson, W. R.; Atwell, G. J.; Schultz, D.; Xu, X. Z.; Denny, W. A. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. 1994, 37, 2175-2184.
17. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Wilson, W. R.; Denny, W. A.; Palmer, B. D.; Knox, R. J.; Friedlos, F.; Williams, A. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 1995, 50, 609-618.
18. Palmer, B. D.; van Zijl, P.; Denny, W. A.; Wilson, W. R. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N- bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. 1995, 38, 1229-1241.
19. Helsby, N. A.; Wheeler, S. J.; Pruijn, F. B.; Palmer, B. D.; Yang, S.; Denny, W. A.; Wilson, W. R. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation. Chem. Res. Toxicol. 2003, 16, 469-478.
20. Johansson, E.; Parkinson, G.; Denny, W. A.; Neidle, S. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J. Med. Chem. 2003, 46, 4009-4020.
21. Friedlos, F.; Denny, W. A.; Palmer, B. D.; Springer, C. J. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem. 1997, 40, 1270-1275.
22. Sum, B. G.; Hicks, K. O.; Pullen, S. M.; van Zijl, P. L.; Denny, W. A.; Wilson, W. R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 2000, 60, 969-978.
23. Atwell, G. J.; Boyd, M.; Palmer, B. D.; Anderson, R. F.; Pullen, S. M.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. Anti-Cancer Drug Des. 1996, 11, 553-567.
24. Jaramillo, P.; Domingo, L. R.; Perez, P. Towards an intrinsic nucleofugality scale: The leaving group (LG) ability in CH3LG model system. Chem. Phys. Lett. 2006, 420, 95-99.
25. Wilson, W. R.; Hicks, K. O.; Pullen, S. M.; Ferry, D. M.; Helsby, N. A.; Patterson, A. V. Bystander effects of bioreductive drugs: potential for exploiting tumor hypoxia with dinitrobenzamide mustards. Rad. Res. 2007, in press.
26. Kestell, P.; Pruijn, F. B.; Siim, B. G.; Palmer, B. D.; Wilson, W. R. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice. Cancer Chemother. Pharmacol. 2000, 46, 365-374.
27. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Hobbs, S. M.; Pruijn, F. B.; Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: Quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Reviews; Springer, C. J., Ed.; Humana Press: Totowa, 2003; pp 403-432.
28. Patterson, A. V.; Saunders, M. P.; Greco, O. Prodrugs in genetic chemoradiotherapy. Curr. Pharm. Des. 2003, 9, 2131-2154.
29. Friedlos, F.; Court, S.; Ford, M.; Denny, W. A.; Springer, C. Gene-directed enzyme prodrug therapy: Quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 1998, 5, 105-112.